(CRSP) Crispr Therapeutics - Overview

Sector: HealthcareIndustry: Biotechnology | Exchange NASDAQ (USA) | Currency USD | Market Cap: 4.457m | Total Return 21.4% in 12m

Stock: Gene Editing, Cell Therapy, Drug Development

Total Rating 29
Risk 84
Buy Signal -0.91
Biotechnology +5.4
Biotechnology +5.9
Market Cap: 4,457m
Avg Trading Vol: 86.9M USD
ATR: 5.86%
Peers RS (IBD): 39.3
Risk 5d forecast
Volatility 53.9%
Relative Tail Risk -11.0%
Reward TTM
Sharpe Ratio 0.55
Alpha -3.90
Character TTM
Beta 1.744
Beta Downside 1.339
Drawdowns 3y
Max DD 64.91%
CAGR/Max DD 0.03

EPS (Earnings per Share)

EPS (Earnings per Share) of CRSP over the last years for every Quarter: "2021-03": -1.51, "2021-06": 9.44, "2021-09": -1.67, "2021-12": -1.84, "2022-03": -2.32, "2022-06": -2.4, "2022-09": -2.24, "2022-12": -1.41, "2023-03": -0.67, "2023-06": -0.98, "2023-09": -1.41, "2023-12": 1.1, "2024-03": -1.43, "2024-06": -1.49, "2024-09": -1.01, "2024-12": -0.44, "2025-03": -1.58, "2025-06": -1.29, "2025-09": -1.17, "2025-12": -1.37,
EPS CAGR: 56.30%
EPS Trend: 21.2%
Last SUE: -0.42
Qual. Beats: 0

Revenue

Revenue of CRSP over the last years for every Quarter: 2021-03: 0.202, 2021-06: 900.202, 2021-09: 0.329, 2021-12: 12.899, 2022-03: 0.178, 2022-06: 0.158, 2022-09: 0.094, 2022-12: 0.006, 2023-03: 100, 2023-06: 70, 2023-09: 0, 2023-12: 200, 2024-03: 0.504, 2024-06: 0.517, 2024-09: 0.602, 2024-12: 35, 2025-03: 0.865, 2025-06: 0.892, 2025-09: 0.889, 2025-12: 0.864,
Rev. CAGR: 52.39%
Rev. Trend: -0.3%
Last SUE: -0.09
Qual. Beats: 0

Risks

Technicals: choppy

Description: CRSP Crispr Therapeutics March 03, 2026

CRISPR Therapeutics AG specializes in gene-based medicines utilizing the CRISPR/Cas9 platform for precise genomic DNA alteration. Headquartered in Zug, Switzerland, the company targets hemoglobinopathies, oncology, autoimmune disorders, and Type 1 Diabetes. Its lead commercial asset, CASGEVY, treats transfusion-dependent beta-thalassemia and severe sickle cell disease by editing hematopoietic stem cells to increase fetal hemoglobin production. The company maintains a strategic partnership with Vertex Pharmaceuticals to advance these therapies.

The companys pipeline includes allogeneic CAR T cell candidates, such as CTX112 and CTX131, alongside in vivo programs addressing cardiovascular targets like angiopoietin-like protein 3. As a biotechnology firm, CRSP operates in a high-risk, high-reward sector where valuation is closely tied to clinical trial outcomes and regulatory milestones rather than immediate cash flow. For a deeper look into these financial metrics and growth projections, ValueRay provides useful research tools.

Headlines to watch out for

  • CASGEVY approval and sales drive revenue growth
  • Clinical trial results impact pipeline valuation
  • Regulatory hurdles delay gene therapy market entry
  • Strategic partnerships provide funding and expertise
  • Research and development costs weigh on profitability

Piotroski VR‑10 (Strict, 0-10) 0.0

Net Income: -581.6m TTM > 0 and > 6% of Revenue
FCF/TA: -0.15 > 0.02 and ΔFCF/TA -8.82 > 1.0
NWC/Revenue: 52.0k% < 20% (prev 5.05k%; Δ 47.0k% < -1%)
CFO/TA -0.15 > 3% & CFO -345.0m > Net Income -581.6m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 13.25 > 1.5 & < 3
Outstanding Shares: last quarter (89.9m) vs 12m ago 5.22% < -2%
Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin)
Asset Turnover: 0.16% > 50% (prev 1.63%; Δ -1.48% > 0%)
Interest Coverage Ratio: -10.57 > 6 (EBITDA TTM -618.9m / Interest Expense TTM -60.4m)

Altman Z'' -5.35

A: 0.81 (Total Current Assets 1.98b - Total Current Liabilities 149.1m) / Total Assets 2.27b
B: -0.86 (Retained Earnings -1.95b / Total Assets 2.27b)
C: -0.28 (EBIT TTM -638.3m / Avg Total Assets 2.25b)
D: -5.65 (Book Value of Equity -1.94b / Total Liabilities 343.4m)
Altman-Z'' Score: -5.35 = D

Beneish M

DSRI: none (Receivables none/25.0m, Revenue 3.51m/36.6m)
GMI: 1.00 (fallback, negative margins)
AQI: 1.51 (AQ_t 0.02 / AQ_t-1 0.01)
SGI: 0.10 (Revenue 3.51m / 36.6m)
TATA: -0.10 (NI -581.6m - CFO -345.0m) / TA 2.27b)
Beneish M-Score: cannot calculate (missing components)

What is the price of CRSP shares?

As of March 27, 2026, the stock is trading at USD 47.55 with a total of 1,260,648 shares traded.
Over the past week, the price has changed by +1.28%, over one month by -22.98%, over three months by -13.67% and over the past year by +21.36%.

Is CRSP a buy, sell or hold?

Crispr Therapeutics has received a consensus analysts rating of 3.96. Therefore, it is recommended to buy CRSP.
  • StrongBuy: 12
  • Buy: 5
  • Hold: 10
  • Sell: 0
  • StrongSell: 1

What are the forecasts/targets for the CRSP price?

Issuer Target Up/Down from current
Wallstreet Target Price 84 76.6%
Analysts Target Price 84 76.6%

CRSP Fundamental Data Overview March 26, 2026

P/E Forward = 23.3645
P/S = 1269.686
P/B = 2.3095
P/EG = -0.2142
Revenue TTM = 3.51m USD
EBIT TTM = -638.3m USD
EBITDA TTM = -618.9m USD
Long Term Debt = 206.7m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 18.6m USD (from shortTermDebt, last quarter)
Debt = 394.9m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 39.7m USD (from netDebt column, last quarter)
Enterprise Value = 2.88b USD (4.46b + Debt 394.9m - CCE 1.98b)
Interest Coverage Ratio = -10.57 (Ebit TTM -638.3m / Interest Expense TTM -60.4m)
EV/FCF = -8.31x (Enterprise Value 2.88b / FCF TTM -345.9m)
FCF Yield = -12.03% (FCF TTM -345.9m / Enterprise Value 2.88b)
FCF Margin = -9.86k% (FCF TTM -345.9m / Revenue TTM 3.51m)
Net Margin = -16.6k% (Net Income TTM -581.6m / Revenue TTM 3.51m)
Gross Margin = unknown ((Revenue TTM 3.51m - Cost of Revenue TTM 226.7m) / Revenue TTM)
Tobins Q-Ratio = 1.27 (Enterprise Value 2.88b / Total Assets 2.27b)
Interest Expense / Debt = 4.51% (Interest Expense 17.8m / Debt 394.9m)
Taxrate = 21.0% (US default 21%)
NOPAT = -504.3m (EBIT -638.3m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 13.25 (Total Current Assets 1.98b / Total Current Liabilities 149.1m)
Debt / Equity = 0.21 (Debt 394.9m / totalStockholderEquity, last quarter 1.92b)
Debt / EBITDA = -0.06 (negative EBITDA) (Net Debt 39.7m / EBITDA -618.9m)
Debt / FCF = -0.11 (negative FCF - burning cash) (Net Debt 39.7m / FCF TTM -345.9m)
Total Stockholder Equity = 1.84b (last 4 quarters mean from totalStockholderEquity)
RoA = -25.81% (Net Income -581.6m / Total Assets 2.27b)
RoE = -31.53% (Net Income TTM -581.6m / Total Stockholder Equity 1.84b)
RoCE = -31.12% (EBIT -638.3m / Capital Employed (Equity 1.84b + L.T.Debt 206.7m))
RoIC = -27.34% (negative operating profit) (NOPAT -504.3m / Invested Capital 1.84b)
WACC = 11.42% (E(4.46b)/V(4.85b) * Re(12.12%) + D(394.9m)/V(4.85b) * Rd(4.51%) * (1-Tc(0.21)))
Discount Rate = 12.12% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 5.15%
[DCF] Fair Price = unknown (Cash Flow -345.9m)
EPS Correlation: 21.15 | EPS CAGR: 56.30% | SUE: -0.42 | # QB: 0
Revenue Correlation: -0.33 | Revenue CAGR: 52.39% | SUE: -0.09 | # QB: 0
EPS next Quarter (2026-06-30): EPS=-1.24 | Chg7d=+0.001 | Chg30d=+0.000 | Revisions Net=+0 | Analysts=19
EPS current Year (2026-12-31): EPS=-4.94 | Chg7d=+0.001 | Chg30d=-0.043 | Revisions Net=-2 | Growth EPS=+23.6% | Growth Revenue=+1269.7%
EPS next Year (2027-12-31): EPS=-4.20 | Chg7d=-0.001 | Chg30d=-0.157 | Revisions Net=+0 | Growth EPS=+15.0% | Growth Revenue=+212.1%
[Analyst] Revisions Ratio: +0.00 (1 Up / 1 Down within 30d for Next Quarter)

Additional Sources for CRSP Stock

Fund Manager Positions: Dataroma | Stockcircle